TORL BioTherapeutics

What TORL BioTherapeutics does

TORL BioTherapeutics LLC is a clinical-stage biopharmaceutical company headquartered in Culver City, California (6100 Bristol Parkway), founded and publicly launched in April 2023 to discover, develop, and commercialize antibody-based therapies for cancer. The company is built around an exclusive research partnership with the Slamon Research Lab at UCLA, which provides a scalable drug-discovery engine for identifying novel antibody targets, antibody candidates, and companion-diagnostic criteria. Its pipeline currently comprises three antibody-drug conjugates (ADCs): the lead asset ixotatug vedotin (Ixo-V; TORL-1-23), a CLDN6-targeted ADC for CLDN6+ solid tumors including platinum-resistant ovarian, non-small cell lung, endometrial, and testicular cancers, currently in a global registration-enabling Phase 2 study (CATALINA-2) with topline data anticipated mid-2027; TORL-4-500, a DLK1-targeted ADC in pre-clinical development; and TORL-5-700, a hematology ADC in early clinical development. All programs target molecular or genetic signatures paired with companion diagnostics to enable patient stratification, and ixotatug vedotin has received FDA Fast Track Designation.

The company's revenue model is contingent on future regulatory approval and commercialization of its ADC pipeline, with no current product revenue disclosed; capital to date has come from multiple venture financings, including a $158M Series B in April 2023 led by Goldman Sachs Asset Management, an oversubscribed $158M Series B-2 in April 2024, and a $96M Series C in October 2025, bringing total funding to over $450M as of May 2026. The go-to-market approach is research-led: TORL advances clinical development through global investigator and clinical-research-network partnerships, generates awareness via presentations at major oncology congresses (ASCO, ESMO), and intends to commercialize through traditional pharmaceutical channels once approved. Its customer set is defined by indication rather than payer, targeting CLDN6-positive cancer patients (starting with platinum-resistant ovarian cancer) and DLK1-positive hematology patients, with the company pairing each therapeutic with a companion diagnostic to ensure the right drug reaches the right patient.

The company is led by CEO Aran Maree, M.D. (formerly CMO at Johnson & Johnson Innovative Medicines, appointed CEO effective May 2026), Chairman Mark Alles (former CEO), CFO/CTO and Co-Founder Dave Licata, CSO Steve Ritland, PhD, COO Christine Loggins, and supported by a board that includes co-founders Dennis Slamon, M.D., PhD (Chief, Hematology-Oncology at UCLA) and Neil O'Brien, PhD (UCLA), alongside representatives from Goldman Sachs Life Sciences, Crescent Capital, Sarah Cannon Research Institute, and PanCAN. The company operates with 51-100 employees and is independently owned by its institutional and strategic investors, with no parent company or controlling entity identified.

Name

TORL BioTherapeutics

Legal name

TORL BioTherapeutics LLC

Website

https://torlbio.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

51–100 employees

Short description

TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer, anchored by lead asset ixotatug vedotin, a CLDN6-targeted ADC in a registrational Phase 2 study for platinum-resistant ovarian cancer, with pipeline programs targeting DLK1 and hematology indications and research rooted in a UCLA Slamon Research Lab partnership.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industry

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening) (HLAAAIAA)

Keywords

• Antibody-drug conjugates
• Oncology therapeutics
• Cancer immunotherapy
• Clinical-stage biopharmaceutical
• Monoclonal antibodies

Headquarters

HQ city

Culver City

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Biopharmaceutical Development and Commercialization: Pre-revenue clinical-stage biopharmaceutical company developing antibody-based cancer therapies. Revenue will be generated upon regulatory approval and commercialization of its ADC pipeline. Programs include ixotatug vedotin (TORL-1-23) in pivotal Phase 2 for platinum-resistant ovarian cancer, with additional programs in preclinical and clinical stages targeting CLDN6 and DLK1.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

TORL BioTherapeutics is a clinical-stage biopharmaceutical company developing antibody-based immunotherapies, primarily antibody-drug conjugates (ADCs), for the treatment of cancer. The company's lead asset, ixotatug vedotin (TORL-1-23), is a CLDN6-targeted ADC currently in pivotal Phase 2 trials for platinum-resistant ovarian cancer. Additional pipeline programs target DLK1 in hematology indications. All programs leverage the company's drug discovery engine developed through a partnership with UCLA's Slamon Research Lab and incorporate companion diagnostics for patient selection.

Product overview

TORL BioTherapeutics is a biopharmaceutical company developing antibody-based therapies for cancer treatment. The company's pipeline includes multiple antibody-drug conjugates (ADCs) and monoclonal antibodies. The lead program is Ixotatug vedotin (TORL-1-23), a CLDN6-targeted ADC in Phase 2 clinical trials for platinum-resistant ovarian cancer and other CLDN6+ solid tumors. Additional pipeline programs include TORL-4-500 (DLK1-targeted ADC in pre-clinical) and TORL-5-700 (ADC for hematology in clinical stage). All programs leverage the company's partnership with UCLA's Slamon Research Lab for biologics-based drug development and include companion diagnostics to ensure targeted patient selection.

Differentiator

Problem solved

Functional benefit

Products and services

• Ixotatug Vedotin (Ixo-V; TORL-1-23) First- and potentially best-in-class clinical-stage antibody-drug conjugate (ADC) targeting Claudin 6 (CLDN6) for the treatment of CLDN6+ solid tumors including ovarian, non-small cell lung, endometrial, and testicular cancers. Has received FDA Fast Track Designation and is being evaluated in the global Phase 2 CATALINA-2 registrational study for platinum-resistant ovarian cancer.
• TORL-4-500 Pre-clinical antibody-drug conjugate (ADC) targeting DLK1 for hematology indications within TORL BioTherapeutics' oncology pipeline.
• TORL-5-700 Clinical-stage antibody-drug conjugate (ADC) targeting an undisclosed indication in hematology within TORL BioTherapeutics' oncology pipeline.

Quantifiable outcome

• 32.1% objective response rate (ORR) and 92.9% disease control rate (DCR) with ixotatug vedotin plus bevacizumab in recurrent ovarian cancer (29 patients)
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• UCLA Slamon Research LabcoreStrategic or Co-development PartnerUnique drug discovery partnership with Slamon Research Lab at UCLA provides scalable technology platform for identification of promising targets, antibodies and patient selection criteria. Dennis Slamon, MD, PhD, serves as Director and Co-Founder and Chief, Hematology-Oncology at UCLA. Neil O'Brien, PhD, serves as Director and Co-Founder and Associate Professor at UCLA.
• Global Clinical Research NetworkscoreStrategic or Co-development PartnerCollaborations with expert clinicians and strategic partnerships with global clinical research networks ensure a streamlined path to bring investigational medicines to patients in need. Conducting pivotal global Phase 2 CATALINA-2 registrational study.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• ProfoundBio: Earlier-stage clinical ADC developer focused on oncology with proprietary linker-payload technology, pursuing overlapping solid tumor indications that intersect with TORL's pipeline strategy.

Direct peers

• Mersana Therapeutics: Clinical-stage biopharmaceutical company developing antibody-drug conjugates for oncology, with a similar pipeline-stage profile and platform-based approach to ADC discovery and development as TORL.
• Pyxis Oncology: Clinical-stage oncology biotech developing antibody-drug conjugates and immunotherapies for difficult-to-treat cancers, sharing TORL's profile as a venture-backed, clinical-stage ADC developer.
• ImmunoGen (AbbVie): Develops ADCs for cancer, including ELAHERE for platinum-resistant ovarian cancer — the same indication as TORL's lead ixotatug vedotin — making it the most directly competing clinical and commercial peer in TORL's lead indication.
• Sutro Biopharma: Clinical-stage oncology company with a proprietary cell-free protein synthesis platform for developing ADCs and other antibody-based therapeutics, mirroring TORL's integrated discovery-to-development ADC approach.
• Bolt Biotherapeutics: Clinical-stage immuno-oncology company developing ADCs with immune-stimulating mechanisms for solid tumors, comparable to TORL in stage, modality (ADC), and oncology focus.

Broad incumbents

• Daiichi Sankyo: Global pharmaceutical leader in ADC technology (e.g., Enhertu partnered with AstraZeneca), with broad oncology pipeline and significantly greater resources, making it a key competitive incumbent to TORL's ADC development.
• AstraZeneca: Major oncology incumbent with a large ADC franchise (via Daiichi Sankyo partnership) and active development in ovarian and lung cancers, representing the type of strategic partner/acquirer that may ultimately commercialize or compete with TORL's assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/torl-biotherapeutics-llc

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds3 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TORL BioTherapeutics